Results 21 to 30 of about 7,331 (198)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction

ESC Heart Failure, 2021
Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medications.
Ying‐Hsiang Lee, Po‐Lin Lin, Wei‐Ru Chiou, Jin‐Long Huang, Wen‐Yu Lin, Chia‐Te Liao, Fa‐Po Chung, Huai‐Wen Liang, Chien‐Yi Hsu, Hung‐Yu Chang   +9 more
doaj   +1 more source

Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study

Cardiology and Therapy, 2020
Introduction Dosing frequency is an important factor influencing medication compliance in patients with heart failure (HF), which in turn is imperative in achieving the desired therapeutic outcome.
Ajit Mullasari, The PROFICIENT investigators   +1 more
doaj   +1 more source

Ivabradine monotherapy in congenital junctional ectopic tachycardia

, 2022
Congenital JET (junctional ectopic tachycardia) is a rare and often difficult to treat tachyarrhythmia in young infants. The addition of Ivabradine to standard Congenital JET therapy has been shown to improve arrhythmia control.
Sivalingam Devaprasath, Siddartha Buddhavarapu, Suja Mariam, Mani Ram Krishna   +3 more
core   +1 more source

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients

ESC Heart Failure, 2021
Aims Ivabradine has been used in patients who have chronic heart failure (HF) with reduced ejection fraction (HFrEF) and concomitant sinus heart rate ≥70 bpm. This administration for acute HFrEF remains a concern. This study used a real‐world multicentre
Chia‐Te Liao, Jin‐Long Huang, Huai‐Wen Liang, Fa‐Po Chung, Ying‐Hsiang Lee, Po‐Lin Lin, Wei‐Ru Chiou, Wen‐Yu Lin, Chien‐Yi Hsu, Hung‐Yu Chang   +9 more
doaj   +1 more source

A pilot study evaluating the role of ivabradine for rate control in patients with rheumatic atrial fibrillation

Indian Heart Journal, 2023
Objectives: Ivabradine may have a role in rate control of atrial fibrillation (AF) due to effects on HCN channels in AV node. We studied role of Ivabradine in rate control of rheumatic AF. Methods: 80 patients, rheumatic AF, HR > 100 bpm (age 47 ± 11 yrs,
Arpita Katheria, Aditya Kapoor, Ankit Sahu, Kamlesh Raut, Harshit Khare, Roopali Khanna, Sudeep Kumar, Naveen Garg, Satyendra Tewari   +8 more
doaj   +1 more source

Ivabradine Prevents Low Shear Stress Induced Endothelial Inflammation and Oxidative Stress via mTOR/eNOS Pathway. [PDF]

PLoS ONE, 2016
Ivabradine not only reduces heart rate but has other cardiac and vascular protective effects including anti-inflammation and anti-oxidation. Since endothelial nitric oxide synthase (eNOS) is a crucial enzyme in maintaining endothelial activity, we aimed ...
Bing Li, Junxia Zhang, Zhimei Wang, Shaoliang Chen   +3 more
doaj   +1 more source

Ivabradine Use in Premature Infants With Accelerated Idioventricular Rhythm. [PDF]

J Cardiovasc Electrophysiol
Introduction: Ivabradine has been recently introduced to treat focal atrial tachycardia and junctional ectopic tachycardia in children. Its use for treating ventricular tachyarrhythmias, specifically accelerated idioventricular rhythm (AIVR), remains ...
Ramdat Misier NL, Doctor PN, Tindel K, de Groot NMS, Ezekian JE, Nguyen HH.   +5 more
europepmc   +2 more sources

Ectopic Atrial Tachycardia in a 12-Month-Old Girl Treated With Ivabradine and Beta-Blocker, a Case Report

Frontiers in Pediatrics, 2020
We report on a 12-month-old girl with an ectopic atrial tachycardia successfully treated with the combination of a beta blocking agent and Ivabradine that acts on cardiac pacemaker cells by selectively inhibiting the If channel.
Holger Michel, Frank Heißenhuber, Sven Wellmann, Michael Melter, Stephan Gerling   +4 more
doaj   +1 more source

Locally injected ivabradine inhibits carrageenan-induced pain and inflammatory responses via hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.

PLoS ONE, 2019
BackgroundRecently, attention has been focused on the role of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the mechanism of and as a treatment target for neuropathic and inflammatory pain.
Saki Miyake, Hitoshi Higuchi, Yuka Honda-Wakasugi, Maki Fujimoto, Hotaka Kawai, Hitoshi Nagatsuka, Shigeru Maeda, Takuya Miyawaki   +7 more
doaj   +1 more source

Identification of the molecular site of ivabradine binding to HCN4 channels.

PLoS ONE, 2013
Ivabradine is a specific heart rate-reducing agent approved as a treatment of chronic stable angina. Its mode of action involves a selective and specific block of HCN channels, the molecular components of sinoatrial "funny" (f)-channels.
Annalisa Bucchi, Mirko Baruscotti, Marco Nardini, Andrea Barbuti, Stefano Micheloni, Martino Bolognesi, Dario DiFrancesco   +6 more
doaj   +1 more source